The specialty drugs ecosystem is developed with blockbuster products, large patient populations and a competitive treatment landscape. Hub services emerged to provide a consistent and predictable experience to patients, prescribers and payers.
But, there has been a shift in the specialty
drugs segment. Today’s market
features precision medicine with a growing
number of highly targeted products,
each with a limited patient population.
Coming down the pipeline is a growing
stream of cell and gene therapies with
even smaller patient populations.
In this Front & Center, you will learn:
- Models for hubs are changing, but the need for them remains constant
- McKesson’s solution is an adaptable model called PharmacyElite
|